Compare Torrent Pharma with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs AJANTA PHARMA - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA AJANTA PHARMA TORRENT PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 59.8 23.5 254.3% View Chart
P/BV x 6.3 4.1 152.6% View Chart
Dividend Yield % 0.8 0.9 95.3%  

Financials

 TORRENT PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
AJANTA PHARMA
Mar-19
TORRENT PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5501,422 109.0%   
Low Rs1,144898 127.4%   
Sales per share (Unadj.) Rs354.7233.5 151.9%  
Earnings per share (Unadj.) Rs40.144.0 91.2%  
Cash flow per share (Unadj.) Rs64.252.2 123.1%  
Dividends per share (Unadj.) Rs14.009.00 155.6%  
Dividend yield (eoy) %1.00.8 134.0%  
Book value per share (Unadj.) Rs273.1255.1 107.1%  
Shares outstanding (eoy) m169.2288.02 192.3%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.85.0 76.5%   
Avg P/E ratio x33.626.4 127.4%  
P/CF ratio (eoy) x21.022.2 94.3%  
Price / Book Value ratio x4.94.5 108.4%  
Dividend payout %34.920.5 170.7%   
Avg Mkt Cap Rs m227,897102,081 223.3%   
No. of employees `00014.76.8 216.2%   
Total wages/salary Rs m11,3534,307 263.6%   
Avg. sales/employee Rs Th4,083.03,022.6 135.1%   
Avg. wages/employee Rs Th772.3633.4 121.9%   
Avg. net profit/employee Rs Th461.3569.1 81.1%   
INCOME DATA
Net Sales Rs m60,02120,554 292.0%  
Other income Rs m2,988211 1,417.6%   
Total revenues Rs m63,00920,765 303.4%   
Gross profit Rs m13,4935,664 238.2%  
Depreciation Rs m4,086721 566.9%   
Interest Rs m3,08512 26,593.1%   
Profit before tax Rs m9,3105,143 181.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,5291,273 198.6%   
Profit after tax Rs m6,7813,870 175.2%  
Gross profit margin %22.527.6 81.6%  
Effective tax rate %27.224.8 109.7%   
Net profit margin %11.318.8 60.0%  
BALANCE SHEET DATA
Current assets Rs m52,62311,812 445.5%   
Current liabilities Rs m52,0223,776 1,377.5%   
Net working cap to sales %1.039.1 2.6%  
Current ratio x1.03.1 32.3%  
Inventory Days Days12077 154.5%  
Debtors Days Days7682 93.4%  
Net fixed assets Rs m85,01614,398 590.5%   
Share capital Rs m846175 482.4%   
"Free" reserves Rs m45,37622,277 203.7%   
Net worth Rs m46,22222,452 205.9%   
Long term debt Rs m41,1157 622,948.5%   
Total assets Rs m142,43226,962 528.3%  
Interest coverage x4.0444.3 0.9%   
Debt to equity ratio x0.90 302,594.7%  
Sales to assets ratio x0.40.8 55.3%   
Return on assets %6.914.4 48.1%  
Return on equity %14.717.2 85.1%  
Return on capital %14.223.0 61.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,58010,682 136.5%   
Fx outflow Rs m3,6002,102 171.3%   
Net fx Rs m10,9808,580 128.0%   
CASH FLOW
From Operations Rs m8,9423,748 238.6%  
From Investments Rs m-47,070-2,228 2,112.6%  
From Financial Activity Rs m34,174-1,475 -2,317.5%  
Net Cashflow Rs m-3,65545 -8,086.3%  

Share Holding

Indian Promoters % 71.5 73.8 96.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 1.6 452.9%  
FIIs % 12.6 7.6 165.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 17.0 51.8%  
Shareholders   26,511 20,968 126.4%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DIVIS LABORATORIES  GLENMARK PHARMA  AUROBINDO PHARMA  PLETHICO PHARMA  FDC LTD.  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Sep 20, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - CADILA HEALTHCARE COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS